Portland’s UbiVac To Detail Progress With New Cancer Therapy at International Immuno-Oncology Forum in Chicago
Contact: Dan Pearson, email@example.com 503.753.7969
May 26, 2015
Portland, Ore.—UbiVac, www.ubivac.com, a private, clinical-stage immuno-oncology company with a lead product that educates the immune system to recognize and destroy cancer, announced that its co-founder, Bernard A. Fox, PhD, will address the 2015 Sachs Immuno-Oncology BD&L and Investment Forum on May 29 in Chicago.
During his remarks, Dr. Fox will detail UbiVac’s DRibble immunotherapy (DPV-001), a first in class technology that combines more than 100 cancer targets including at least 13 National Cancer Institute (NCI) prioritized cancer antigens. Research suggests that DRibble technology is novel and can overcome tolerance; inducing immunity against cancer. UbiVac believes that DRibble technology is the ideal companion for combination immunotherapy and fills a gap in the pipeline of all major pharmaceutical companies currently in the immuno-oncology space. UbiVac’s lead candidate, DPV-001, is currently in an NCI-supported randomized multi-center Phase II clinical trial.
Dr. Fox will outline positive early results documenting induction of immunity against a wide spectrum of cancer targets in patients with non-small cell lung cancer (NSCLC). “We are excited that early results document that DPV-001 is educating the immune system of patients so they can recognize their cancer, Dr. Fox said. He added, “UbiVac is already planning a 270-300 patient phase I/II trial that will combine DPV-001 with Opdivo, recently approved by the US FDA for patients with metastatic squamous NSCLC.” Based on animal studies, Fox believes the combination of Opdivo and DPV-001 will substantially increase the response rate and improve overall survival. UbiVac’s technology is already in a clinical trial for men with prostate cancer and will soon open for patients with breast cancer.
Award Number R44CA121612 from the National Cancer Institute supports the ongoing research and clinical trial of DPV-001.
The Sachs Immuno-Oncology: BD&L and Investment Forum, www.sachsforum.com is designed to bring together thought leaders from cancer research institutes, patient advocacy groups, pharmaceutical and biotechnology to facilitate partnering, funding and investment. The one-day meeting is expected to draw about 200 delegates, and an online meeting system will make the event transactional. Tracks will include presentations by both listed and private biotechnology companies.
Sachs Associates is considered to have significant knowledge of key individuals operating within the European and global biotech field, putting the firm at the forefront of the industry and, through this annual Forum, providing an effective platform for companies like UbiVac to gain recognition among collaborators and funders.
UbiVac is a clinical stage immuno-oncology company engaged in research and development of therapeutic immunotherapies to combat cancer. Founded in Portland, Ore. In 2005, it is a spinout of the Robert W. Franz Cancer Research Center within the Earle A. Chiles Research Institute at Providence Medical Center. In 2011 UbiVac, in cooperation with Oregon Health & Science University, created UbiVac CMV Inc., to license a disabled cytomegalovirus (CMV) vector technology for use as a vaccine. This technology is actively being developed in collaboration with other research partners. The company’s co-founder, president and CEO, Bernard A. Fox, PhD, holds the Harder Family Endowed Chair for Cancer Research and is member and Chief, Laboratory of Molecular and Tumor Immunology at the Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute, Providence Cancer Center.